DeepMed Research

Lipoic acid

Generic Name: Lipoic acid

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄O_₂S_₂

CAS Number: 1200-22-2

Unique Ingredient Identifier: VLL71EBS9Z

Background: A vitamin-like antioxidant.

Indication: For nutritional supplementation, also for treating dietary shortage or imbalance.

Associated Conditions: Diabetic Neuropathies, Type 2 Diabetes Mellitus

Associated Therapies: Dietary and Nutritional Therapies, Nutritional supplementation

Clinical Trials

The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion

Phase 4

Completed

Conditions: Type 2 Diabetes
Prediabetes

Interventions: Drug: alpha lipoic acid

First Posted Date: 2010-01-26

Last Posted Date: 2012-10-02

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 15

Registration Number: NCT01056497

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

Phase 3

Completed

Conditions: Diabetic Polyneuropathy

Interventions: Drug: Placebo
Drug: Thioctic Acid

First Posted Date: 2009-09-15

Last Posted Date: 2022-02-07

Lead Sponsor: MEDA Pharma GmbH & Co. KG

Target Recruit Count: 460

Registration Number: NCT00977483

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇳🇱
University Hospital Utrecht Department of Internal Medicine, Utrecht, Netherlands
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 35 locations

Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

Phase 2

Completed

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
CIDP

Interventions: Drug: lipoic acid

First Posted Date: 2009-08-20

Last Posted Date: 2020-08-19

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 7

Registration Number: NCT00962429

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2007-06-25

Last Posted Date: 2018-03-20

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 30

Registration Number: NCT00490867

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

Phase 2

Completed

Conditions: Ototoxicity
Unspecified Adult Solid Tumor

Interventions: Drug: alpha-lipoic acid
Behavioral: Audiology
Biological: laboratory biomarker analysis
Drug: Placebo

First Posted Date: 2007-05-24

Last Posted Date: 2014-03-07

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 39

Registration Number: NCT00477607

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
VA Medical Center, Portland, Portland, Oregon, United States

The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes

Phase 2

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lipoic acid

First Posted Date: 2006-11-14

Last Posted Date: 2024-05-29

Lead Sponsor: University of Edinburgh

Registration Number: NCT00398892

Locations: 🇬🇧
Diabetes Department, St John's Hospital, Livingston, Scotland, United Kingdom

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

Phase 3

Completed

Conditions: Diabetic Polyneuropathy

First Posted Date: 2006-05-22

Last Posted Date: 2022-02-07

Lead Sponsor: MEDA Pharma GmbH & Co. KG

Target Recruit Count: 170

Registration Number: NCT00328601

Locations: 🇷🇺
Chair of Nervous Diseases of IM Sechenov Moscow Medical Academy at City Clinical Hospital, Moscow, Russian Federation
🇮🇱
Haddassah Medical Center Ein Kerem, Diabetes Unit, Jerusalem, Israel
🇷🇺
Chair of Endocrinology and Diabetology of Russian Medical Academy of Postgraduate Education at Central Clinical Hospital of Ministry of Communication RF, Moscow, Russian Federation

and more 2 locations

Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)

Phase 2

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Alpha, gamma, beta, and delta (mixed) tocopherols
Drug: placebo
Drug: alpha lipoic acid

First Posted Date: 2006-03-30

Last Posted Date: 2009-07-09

Lead Sponsor: Vanderbilt University

Target Recruit Count: 62

Registration Number: NCT00308971

Locations: 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

Phase 2

Completed

Conditions: End-stage Renal Disease

Interventions: Drug: Alpha, gamma, beta, and delta (mixed) tocopherols
Drug: Placebo
Drug: Alpha lipoic acid

First Posted Date: 2005-10-12

Last Posted Date: 2012-01-11

Lead Sponsor: Vanderbilt University

Target Recruit Count: 385

Registration Number: NCT00237718

Locations: 🇺🇸
Fresenius Medical Care North America, Nashville, Tennessee, United States

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

Not Applicable

Completed

Conditions: Impaired Glucose Tolerance
Prediabetic State

Interventions: Drug: Aspirin
Drug: Olmesartan
Drug: Placebo
Drug: Alpha lipoic acid

First Posted Date: 2005-07-22

Last Posted Date: 2013-12-05

Lead Sponsor: Emory University

Target Recruit Count: 84

Registration Number: NCT00122447

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy